摘要
目的研究钙离子拮抗剂非洛地平缓释片治疗肾性高血压的疗效及安全性。方法将142例确诊为肾性高血压的患者随机分为非洛地平治疗组(83例)和福辛普利对照组(59例)两组,共治疗8周,检测血压、肾功能、尿蛋白、心率、服药情况及副反应发生情况等。结果治疗8周后,非洛地平组与福辛普利组的血压下降程度分别为(25.63±11.80)/(12.18±9.07)mmHg、(21.87±10.72)/(11.93±8.98)mmHg,两组无明显差异(P>0.05);两组的总有效率分别为91.45%(76/83)和89.66%(53/59),两组疗效无明显差异(P>0.05);两组的不良反应发生率分别为9.64%、11.86%,两组无明显差异(P>0.05),但福辛普利组咳嗽发生率为11.86%,显著高于非洛地平组(0.00%)(P<0.01)。结论非洛地平缓释片治疗肾性高血压具有良好的疗效和安全性。
Objective To study the therapeutic efficacy and safety of felodipine in the therapy for renal hypertension. Methods One hundred fourty two patients that remal hypertension were diagnosed were randomly allocated into two groups to be treated for 8 weeks： felodipine treated group（83 cases） and Fosinpril divided group（59 cases）. The blood pressure, renal function, urea protein, heart rate, administration status and adverse reactions of the patients were observed during treating time. Rusults After 8 weeks of treatment, the blood pressure in felodipine group and Fosinpril group were reduced by （25.63±11.80）/（12.18±9.07） mmHg, （21.87±10.72）/（11.93±8.98） mmHg respectively, which were not significant（ P 〉 0.05） . The total effective rate in felodipine group and Fosinpril group were 91.45% （76/83） and 89.66% （53/59） respectively,which were not significant（ P 〉 0.05）. The total adverse event incidences in felodipine group and Fosinpril group were 9.64%, 11.86% respectively, which were not significant（ P 〈 0. 05）, （8.47%） was significantly higher than that in the Felodipine has a better efficacy and is safe in the However, the cough incidence in Fosinpril group felodipine group（0.00% ）（ P 〈 0. 01 ）. Conclusion therapy for renal hypertension.
出处
《苏州大学学报（医学版）》
CAS
北大核心
2007年第1期108-110,共3页
Suzhou University Journal of Medical Science
